Core Viewpoint - The report from CICC indicates that Haijia Medical (06078) experienced a significant decline in sales and profits in the first half of the year, primarily due to factors such as centralized drug procurement, the implementation of DRGs, and macroeconomic uncertainties [1] Financial Performance - Haijia Medical's sales decreased by 16% year-on-year [1] - Operating profit fell by 42% [1] - Net profit declined by 36% [1] - Adjusted net profit dropped by 34%, aligning with previous forecasts [1] Future Projections - CICC has revised its revenue forecasts for 2025 to 2027 down by 18% to 26% [1] - Net profit forecasts have been reduced by 19% to 27% [1] - The target price for Haijia Medical has been slightly lowered from HKD 17.3 to HKD 17 [1] - The rating remains "Outperform" [1] Key Focus Areas - The current priority is to improve profit margins driven by increased hospital utilization [1]

智通财经APP获悉，里昂发布研报称，海吉亚医疗(06078)上半年销售额同比跌16%，经营利润跌42%， 净利润跌36%，经调整净利润跌34%，与预告一致。业绩下跌主要受药品集中采购(GPO)、疾病诊断相 关组(DRG)实施及宏观经济不确定性影响。该行认为现有医院利用率提升带动利润率改善是目前的优先 关注点，将2025至27年收入预测下调18%至26%，净利润预测下调19%至27%;目标价由17.3港元微降至 17港元，并维持"跑赢大市"评级。 ...